Holen Sie sich die Stockscreener-App
175.84
2.55%
-4.60
Handel nachbörslich:
175.60
-0.24
-0.14%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$180.44
Offen:
$179.91
24-Stunden-Volumen:
1.51M
Relative Volume:
0.85
Marktkapitalisierung:
$25.80B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.53B
KGV:
16.82
EPS:
10.453
Netto-Cashflow:
$1.85B
1W Leistung:
-2.41%
1M Leistung:
+13.07%
6M Leistung:
+31.08%
1J Leistung:
+12.39%
1-Tages-Spanne:
$175.39
$181.99
1-Wochen-Bereich:
$175.39
$183.15
52-Wochen-Spanne:
$110.03
$185.17
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
175.84 | 26.47B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
982.22 | 892.86B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
199.96 | 485.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
222.99 | 394.34B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.01 | 249.77B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
96.89 | 245.55B | 63.90B | 19.05B | 13.05B | 7.5596 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Marshall Wace LLP Boosts Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen (SUPN) gains Health Canada NOC for ZURZUVAE in postpartum depression treatment - Stock Titan
Amundi Cuts Position in Biogen Inc. $BIIB - MarketBeat
Eisai and Biogen's LEQEMBI® Added to China's Commercial Insurance Innovative Drug List, Enhancing Access to Alzheimer's Treatment - Quiver Quantitative
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List - Biogen
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List - GlobeNewswire Inc.
Biogen (BIIB): Assessing Valuation After Promising New Zorevunersen Data in Dravet Syndrome - simplywall.st
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business? - The Globe and Mail
Is Biogen Stock Outperforming the Dow? - Barchart.com
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025 - marketscreener.com
Invesco Ltd. Increases Stock Position in Biogen Inc. $BIIB - MarketBeat
Lido Advisors LLC Has $647,000 Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Stake Reduced by Schroder Investment Management Group - MarketBeat
Biogen Inc. $BIIB Shares Bought by Guggenheim Capital LLC - MarketBeat
First Trust Advisors LP Acquires 212,403 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen (BIIB) Advances Potential Treatment for Dravet Syndrome w - GuruFocus
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz
BIIB: Promising Data for Biogen's Zorevunersen in Dravet Syndrome Treatment - GuruFocus
Stoke Therapeutics and Biogen present data that further support the disease-modifying potential of zorevunersen - marketscreener.com
Stoke, Biogen Present Positive Long-Term Results For Zorevunersen In Dravet Syndrome - Nasdaq
Biogen and Stoke Therapeutics present data that further support the disease-modifying potential of zorevunersen - marketscreener.com
Stoke Therapeutics, Inc. and Biogen Present Data on Zorevunersen at AES 2025 - TradingView
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting - The Manila Times
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting - Business Wire
American Century Companies Inc. Increases Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Stoke Therapeutics: A Long-Term Biotech Growth PlayWhy I Assign A Hold Rating (STOK) - Seeking Alpha
Key facts: Biogen's Alzheimer's drug delays progression by 30%; CEO boosts shares - TradingView
New York State Common Retirement Fund Increases Stake in Biogen Inc. $BIIB - MarketBeat
Biogen Shares New Leqembi Data on Slower Alzheimer's Progression, Injection Option - marketscreener.com
Biosimilars and Biologics Market is expected to reach US$ - openPR.com
Arrowstreet Capital Limited Partnership Grows Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Should New LEQEMBI Data and Subcutaneous Option Shift the Risk Profile for Biogen (BIIB) Investors? - simplywall.st
Biogen (BIIB) Reports Promising Lecanemab Findings for Alzheimer's Treatment - GuruFocus
Eisai and Biogen Present Long-Term LEQEMBI Data Indicating Potential Delay in Alzheimer's Disease Progression by Up to 8.3 Years - Quiver Quantitative
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Con - StreetInsider
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 - PR Newswire
Biogen’s strategic turn to New Ventures - BioCentury
BIIB: Felzartamab and lupus assets advance in late-stage trials, targeting major unmet needs - TradingView
Mackenzie Financial Corp Boosts Stake in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Stake Reduced by Fisher Asset Management LLC - MarketBeat
Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference - marketscreener.com
Biogen (BIIB) Sees Promising Lecanemab Results in Alzheimer's Tr - GuruFocus
Lecanemab shows effect on Alzheimer’s biomarkers in new study By Investing.com - Investing.com India
Biogen (BIIB): Assessing Valuation After Recent Share Price Gains - Yahoo Finance
Lecanemab shows effect on Alzheimer’s biomarkers in new study - Investing.com
Eisai and Biogen Present New Findings on Lecanemab's Effects on Alzheimer’s Disease at CTAD Conference - Quiver Quantitative
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF - PR Newswire
I Remember Aduhelm. The Return of Roche in Alzheimer’s Is a Turning Point - BioSpace
Biogen Inc.: Financial Data Forecasts Estimates and Expectations | BIIB | US09062X1037 - marketscreener.com
Does Biogen’s Valuation Stack Up After Recent Alzheimer’s Regulatory Updates? - simplywall.st
Multiple Sclerosis Therapeutics Market Growth Accelerates - openPR.com
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):